Curis Inc (NASDAQ:CRIS)
| 0.72 Delayed Data As of May 27 |  -0.0085 / -1.17%Today’s Change | 0.70 Today|||52-Week Range 15.60 | -84.87% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $66.0M |
Company Description
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Contact Information
Curis, Inc. 128 Spring Street Lexington Massachusetts 02421 |
Employees
Shareholders
| Other institutional | 44.74% |
| Mutual fund holders | 22.66% |
| Individual stakeholders | 0.27% |
Top Executives
| James E. Dentzer | President, Chief Executive Officer & Director |
| William E. Steinkrauss | Chief Financial & Administrative Officer |
| Mark W. Noel | VP-Technology Management & Intellectual Property |
| Robert E. Martell | Head-Research & Development |
| Reinhard von Roemeling | Senior Vice President-Clinical Development |
